Emily M. Leproust Sells 492 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 492 shares of the stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $38.73, for a total value of $19,055.16. Following the completion of the sale, the chief executive officer now owns 660,474 shares of the company’s stock, valued at approximately $25,580,158.02. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Twist Bioscience Stock Down 3.5 %

NASDAQ:TWST opened at $36.19 on Monday. The stock has a 50-day simple moving average of $43.80 and a 200 day simple moving average of $45.07. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90. The company has a market capitalization of $2.16 billion, a price-to-earnings ratio of -10.71 and a beta of 2.34. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period in the previous year, the business earned ($0.75) EPS. The business’s quarterly revenue was up 24.1% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on TWST shares. Barclays set a $58.00 target price on Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Robert W. Baird lifted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $54.10.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Versant Capital Management Inc raised its stake in Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock worth $27,000 after acquiring an additional 580 shares during the period. Wilmington Savings Fund Society FSB bought a new position in shares of Twist Bioscience during the third quarter valued at approximately $34,000. Van ECK Associates Corp raised its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Banque Transatlantique SA bought a new stake in shares of Twist Bioscience in the 4th quarter worth approximately $43,000. Finally, GF Fund Management CO. LTD. acquired a new position in Twist Bioscience during the 4th quarter valued at approximately $58,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.